{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:56:00Z","timestamp":1784141760574,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Department of Primary Care. Ger\u00e8ncia Territorial de Barcelona. Catalan Institute of Health","award":["XB2021."],"award-info":[{"award-number":["XB2021."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40261-022-01144-8","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:04:41Z","timestamp":1650539081000},"page":"417-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence of Gabapentinoids and Central Nervous System Depressant Drugs, and Their Association with Risk Factors for Respiratory Depression in Primary Care Patients"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-1463","authenticated-orcid":false,"given":"Eladio","family":"Fern\u00e1ndez-Liz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Estrella","family":"Barcel\u00f3-Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"G\u00f3mez-Ganda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Varon-Galcera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lalueza-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Medel-Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Hortelano-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Mart\u00edn-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"issue":"2","key":"1144_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40122-020-00189-x","volume":"9","author":"H Mcanally","year":"2020","unstructured":"Mcanally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther. 2020;9(2):441\u201352. https:\/\/doi.org\/10.1007\/s40122-020-00189-x.","journal-title":"Pain Ther"},{"key":"1144_CR2","unstructured":"Lyrica: EPAR - Product information. 2009. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lyrica. Accessed 1 Nov 2021"},{"key":"1144_CR3","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1371\/journal.pmed.1002396","volume":"14","author":"T Gomes","year":"2017","unstructured":"Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson van den JMBW. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14:2396.","journal-title":"PLoS Med"},{"issue":"1","key":"1144_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1213\/00000539-200007000-00035","volume":"91","author":"K Eckhardt","year":"2000","unstructured":"Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000;91(1):185\u201391. https:\/\/doi.org\/10.1213\/00000539-200007000-00035.","journal-title":"Anesth Analg"},{"key":"1144_CR5","unstructured":"U.S. Food and Drug Administration. FDA warns about serious breathing problems seizure and nerve pain medicines gabapentin (neurontin, gralise, horizant) and pregabalin (lyrica, lyrica CR). 2017. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Accessed 1 Nov 2021"},{"key":"1144_CR6","unstructured":"Medicines and Healthcare products Regulatory Agency. Gabapentin (neurontin): risk of severe respiratory depression. 20217. https:\/\/www.gov.uk\/drug-safety-update\/gabapentin-neurontin-risk-of-severe-respiratory-depression#risk-of-respiratory-depression. Accessed 1 Nov 2021"},{"key":"1144_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0359-y","author":"S Chiappini","year":"2016","unstructured":"Chiappini S, Schifano F. Decade of gabapentinoid misuse\u202f: an analysis of the European Medicines Agency\u2019s \u00ab\u202fSuspected Adverse Drug Reactions\u00bb Database. CNS Drugs. 2016. https:\/\/doi.org\/10.1007\/s40263-016-0359-y.","journal-title":"CNS Drugs"},{"issue":"8","key":"1144_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","volume":"15","author":"KE Evoy","year":"2019","unstructured":"Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm. 2019;15(8):953\u20138. https:\/\/doi.org\/10.1016\/j.sapharm.2018.06.018 (Epub 2018 Jun 28 PMID: 31303196).","journal-title":"Res Social Adm Pharm"},{"key":"1144_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.639780","author":"M Tambon","year":"2021","unstructured":"Tambon M, Pont\u00e9 C, Jouanjus E, Fouilh\u00e9 N, Micallef J, Lapeyre-Mestre M. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psychiatry. 2021. https:\/\/doi.org\/10.3389\/fpsyt.2021.639780.","journal-title":"Front Psychiatry"},{"issue":"12","key":"1144_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","volume":"43","author":"S H\u00e4gg","year":"2020","unstructured":"H\u00e4gg S, J\u00f6nsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Saf. 2020;43(12):1235\u201354. https:\/\/doi.org\/10.1007\/s40264-020-00985-6.","journal-title":"Drug Saf"},{"issue":"April","key":"1144_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.676224","volume":"12","author":"F Fonseca","year":"2021","unstructured":"Fonseca F, Lenahan W, Dart RC, et al. Non-medical use of prescription gabapentinoids (Gabapentin and Pregabalin) in five European countries. Front Psychiatry. 2021;12(April):1\u201310. https:\/\/doi.org\/10.3389\/fpsyt.2021.676224.","journal-title":"Front Psychiatry."},{"issue":"4","key":"1144_CR12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/bcp.14537","volume":"87","author":"J Hockenhull","year":"2021","unstructured":"Hockenhull J, Amioka E, Black JC, et al. Non-medical use of benzodiazepines and GABA analogues in Europe. Br J Clin Pharmacol. 2021;87(4):1684\u201394. https:\/\/doi.org\/10.1111\/bcp.14537.","journal-title":"Br J Clin Pharmacol"},{"key":"1144_CR13","unstructured":"European Medicines Agency. PRAC recommendations on signals. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-6-9-june-2017-prac-meeting_en.pdf. Accessed 1 Nov de 2021"},{"key":"1144_CR14","unstructured":"Pregabalin (Lyrica): reports of severe respiratory depression. 2021. https:\/\/www.gov.uk\/drug-safety-update\/pregabalin-lyrica-reports-of-severe-respiratory-depression#fn:1. Accessed 1 Nov 2021"},{"key":"1144_CR15","unstructured":"Dades B\u00e0siques de Salut (DBS). SI9SAP. ICS. https:\/\/si9sapics.wordpress.com\/productes-dbs\/. Accessed 1 Nov 2021"},{"key":"1144_CR16","unstructured":"Official statistics of Catalonia. Statistical Institute of Catalonia. https:\/\/www.idescat.cat\/. Accessed 1 Mar 2022"},{"issue":"1","key":"1144_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/01.mlr.0000102367.93252.70","volume":"42","author":"JS Hughes","year":"2004","unstructured":"Hughes JS, Averill RF, Eisenhandler J, Goldfield NI, Muldoon J, Neff JM, Gay JC. Clinical Risk Groups (CRGs): a classification system for risk-adjusted capitation-based payment and health care management. Med Care. 2004;42(1):81\u201390. https:\/\/doi.org\/10.1097\/01.mlr.0000102367.93252.70.","journal-title":"Med Care"},{"issue":"10","key":"1144_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.aprim.2016.06.003","volume":"48","author":"D Monterde","year":"2016","unstructured":"Monterde D, Vela E, Cl\u00e8ries M, grupo colaborativo GMA. Adjusted morbidity groups: a new multiple morbidity measurement of use in Primary Care. Aten Primaria. 2016;48(10):674\u201382. https:\/\/doi.org\/10.1016\/j.aprim.2016.06.003 (Spanish).","journal-title":"Aten Primaria"},{"key":"1144_CR19","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. 2020. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 1 Nov 2021"},{"key":"1144_CR20","unstructured":"Health Departament. Bases for a Catalan model of care for people with complex needs. Health plan. 2017. https:\/\/salutweb.gencat.cat\/web\/.content\/_ambits-actuacio\/Linies-dactuacio\/Estrategies-de-salut\/Cronicitat\/Documentacio-cronicitat\/arxius\/bases_modelo_personas_complejidad_v_6.pdf. Accessed 1 Nov 2021"},{"key":"1144_CR21","unstructured":"EPAR - Product information. 2009. European Medicines Agency. https:\/\/www.ema.europa.eu\/en. Accessed 1 Nov 2021"},{"issue":"4","key":"1144_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008 (PMID: 18313558).","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1144_CR23","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, S\u00f8rensen HT, von Elm E, Langan SM, RECORD Working Committee. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885.","journal-title":"PLoS Med"},{"key":"1144_CR24","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2018.12358","volume":"320","author":"F Montastruc","year":"2018","unstructured":"Montastruc F, Loo SYRC. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017. JAMA. 2018;320:2149\u201351. https:\/\/doi.org\/10.1001\/jama.2018.12358.","journal-title":"JAMA"},{"key":"1144_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bja.2020.05.017","volume":"125","author":"N Torrance","year":"2020","unstructured":"Torrance N, Veluchamy A, Zhou Y, Fletcher EH, Moir E, Hebert HL, Donnan PT, Watson J, Colvin LASB. Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. Br J Anaesth. 2020;125:159\u201367. https:\/\/doi.org\/10.1016\/j.bja.2020.05.017.","journal-title":"Br J Anaesth"},{"key":"1144_CR26","doi-asserted-by":"publisher","unstructured":"Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178(2):292\u20134. https:\/\/doi.org\/10.1001\/jamainternmed.2017.7856.","DOI":"10.1001\/jamainternmed.2017.7856"},{"issue":"1","key":"1144_CR27","doi-asserted-by":"publisher","first-page":"bjgpopen20X1011","DOI":"10.3399\/bjgpopen20X101120","volume":"5","author":"AL Schaffer","year":"2021","unstructured":"Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. Pregabalin prescribing patterns in Australian general practice, 2012\u20132018: a cross-sectional study. BJGP Open. 2021;5(1):bjgpopen20X101120. https:\/\/doi.org\/10.3399\/bjgpopen20X101120.","journal-title":"BJGP Open."},{"key":"1144_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40261-021-01009-6","volume":"41","author":"EA Ibiloye","year":"2021","unstructured":"Ibiloye EA, Barner JC, Lawson KA, Rascati KL, Evoy KEPA. Prevalence of and factors associated with gabapentinoid use and misuse among texas medicaid recipients. Clin Drug Investig. 2021;41:245\u201353.","journal-title":"Clin Drug Investig"},{"key":"1144_CR29","doi-asserted-by":"crossref","unstructured":"Zhou L, Bhattacharjee S, Kwoh CK, et\u00a0al. Trends , patient and prescriber characteristics in gabapentinoid use in a sample of United States Ambulatory Care Visits from 2003 to 2016. Published online 2020:1-8.","DOI":"10.3390\/jcm9010083"},{"key":"1144_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.aprim.2011.06.009","volume":"44","author":"MJ Sim\u00f3","year":"2012","unstructured":"Sim\u00f3 MJ. Use of prescription drugs in Spain and Europe. Aten Primaria. 2012;44:335\u201347. https:\/\/doi.org\/10.1016\/j.aprim.2011.06.009.","journal-title":"Aten Primaria"},{"key":"1144_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2125.2007.03029.x","volume":"65","author":"E Fern\u00e1ndez-liz","year":"2008","unstructured":"Fern\u00e1ndez-liz E, Modamio P, Catal\u00e1n A, Lastra CF, Rodr\u00edguez T, Mari\u00f1o EL. Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain. Br J Clin Pharmacol. 2008;65:407\u201317. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03029.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1144_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/ALN.0000000000000913","volume":"124","author":"M Myhre","year":"2016","unstructured":"Myhre M, Diep LMSA. Pregabalin has analgesic, ventilatory, and cognitive effects in combination with remifentanil. Anesthesiology. 2016;124:141\u20139.","journal-title":"Anesthesiology"},{"key":"1144_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1213\/ANE.0000000000001719","volume":"125","author":"AN Cavalcante","year":"2017","unstructured":"Cavalcante AN, Sprung J, Schroeder DR, Weingarten TN. Multimodal analgesic therapy with gabapentin and its association with postoperative respiratory depression. Anesth Analg. 2017;125:141\u20136. https:\/\/doi.org\/10.1213\/ANE.0000000000001719.","journal-title":"Anesth Analg"},{"issue":"5","key":"1144_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1155\/2011\/561604","volume":"16","author":"N Eipe","year":"2011","unstructured":"Eipe N, Penning J. Postoperative respiratory depression associated with pregabalin: a case series and a preoperative decision algorithm. Pain Res Manag. 2011;16(5):353\u20136. https:\/\/doi.org\/10.1155\/2011\/561604","journal-title":"Pain Res Manag"},{"key":"1144_CR35","doi-asserted-by":"publisher","unstructured":"Schaffer AL, Busingye D, Chidwick K, Brett J, Blogg S. Pregabalin prescribing patterns in Australian general practice , 2012\u20132018\u202f: a cross-sectional study. Published online 2020:2012-2018. doi: https:\/\/doi.org\/10.3399\/bjgpopen20X101120","DOI":"10.3399\/bjgpopen20X101120"},{"key":"1144_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.aprim.2011.07.018","volume":"44","author":"J Velert Vila","year":"2012","unstructured":"Velert Vila J, del Velert Vila MM, Salar Ib\u00e1\u00f1ez L, Avellana Zaragoza JAMRL. Suitability of the use of benzodiazepines prescribed by the pharmacist in the elderly. A doctor-pharmacist collaboration study. Aten Primaria. 2012;44:402\u201310. https:\/\/doi.org\/10.1016\/j.aprim.2011.07.018.","journal-title":"Aten Primaria"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01144-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T03:36:09Z","timestamp":1652499369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01144-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01144-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"22 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Atenci\u00f3 Prim\u00e0ria Barcelona Ciutat, Institut Catal\u00e0 de la Salut (XB2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with all applicable laws and regulations and ethical principles originating from the Declaration of Helsinki. The protocol was approved by the University Institute for Primary Care Research (IDIAP) Jordi Gol Ethics Committee (Barcelona) (reference number: 21\/122-P). Data confidentiality was guaranteed throughout the study process and the data available for research purposes were anonymized. Because the data obtained underwent a pseudonymization process and the research team did not have access to the patients\u2019 information, the ethics committee did not consider patient informed consent necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All available data are included in the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design, analysis and interpretation of the data, and critical revision of the manuscript. The first draft of the manuscript was written by EFL and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}